Kiniksa Pharmaceuticals, Ltd. (KNSA)

19.53 -0.66 (-3.27%) 收市：04:00PM EDT

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

https://www.kiniksa.com

版塊: Healthcare
行業: Biotechnology
全職員工: 297

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Sanj K. Patel	CEO & Chairman of the Board	1.57M	無	1969
Mr. Eben Tessari	Senior VP & COO	733.29k	無	1982
Dr. John F. Paolini FACC, M.D., Ph.D.	Senior VP & Chief Medical Officer	855.79k	無	1965
Mr. Mark Ragosa C.F.A.	Senior VP & CFO	無	無	1974
Mr. Michael R. Megna CPA	Chief Accounting Officer & Group VP of Finance	無	無	1971
Ms. Mei Jang	Senior VP of Technical Operations	無	無	無
Rachel Frank	Associate Director of Investor Relations	無	無	無
Mr. Chad Morin	Senior VP & Chief Compliance Officer	無	無	無
Ms. Madelyn Demsky Zeylikman	SVP, General Counsel & Secretary	無	無	1974
Ms. Melissa Manno	Senior VP & Chief Human Resources Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

公司管治

截至 2024年5月1日 止，Kiniksa Pharmaceuticals, Ltd. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：7；董事會：9；股東權利：10；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。